Upstream Bio, Inc. (UPB)
NasdaqGS · USD · Healthcare · Biotechnology
$2.75 (+0.36%) as of
Key statistics
- Market cap
- 150.62M
- Forward P/E
- -0.98
- EPS (TTM)
- -2.8800
- Dividend yield
- 0.00%
- 52-week range
- 2.6950 – 33.6800
- Beta
- 1.39
- Revenue (TTM)
- 3.16M
- Profit margin
- 0.00%
- Analyst target
- $29.83
- Volume
- 983.84k
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Waltham, MA, United States
- Employees
- 75
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.